NCT04443036 is a NA clinical trial of Albumin-Bound Paclitaxel in Gastric Carcinoma, sponsored by China Medical University, China.

Who is sponsoring NCT04443036?

NCT04443036 is sponsored by China Medical University, China.

What drugs are being tested in NCT04443036?

Interventions in NCT04443036: Albumin-Bound Paclitaxel, Toripalimab.

What condition does NCT04443036 study?

NCT04443036 studies Gastric Carcinoma.

Is NCT04443036 still recruiting?

NCT04443036 is currently status unknown. Last updated 23 June 2020.

Last reviewed 2020-06-23 · How we verify

NCT04443036

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma

Status unknown NA Last updated 23 June 2020

What this trial tests

NA trial testing Albumin-Bound Paclitaxel in Gastric Carcinoma in 44 participants. Status unknown.

Timeline

11 June 2020

Primary endpoint
30 December 2022

30 December 2023

Quick facts

Lead sponsor	China Medical University, China
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	44
Start date	11 June 2020
Primary completion	30 December 2022
Estimated completion	30 December 2023
Sites	1 location across China

Drugs / interventions tested

Albumin-Bound Paclitaxel — full drug profile →
Toripalimab (TORIPALIMAB) — full drug profile →

Conditions studied

Gastric Carcinoma — all drugs for Gastric Carcinoma →

Sponsor

China Medical University, China

Who can join

Adults 18 to 70, any sex, with Gastric Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to evaluate the efficacy and safety of Albumin-bound paclitaxel combined with Toripalimab as first-line/second-line treatment of local advanced or metastatic gastric or gastroesophageal junction carcinoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?
Timon-David E, Perez C, Rodallec A. · · 2022 · cited 2× · PMID 36365144 · DOI 10.3390/pharmaceutics14112326

Verify or expand the search:

Other trials of Albumin-Bound Paclitaxel

Trials testing the same drug.

NCT07046221 — Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery · Phase 2 · not yet recruiting
NCT06939270 — CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors · Phase 1, PHASE2 · not yet recruiting
NCT06692491 — Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · Phase 2 · not yet recruiting
NCT06725498 — Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC · Phase 2 · recruiting
NCT06647563 — Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT) · Phase 3 · not yet recruiting

Other recruiting trials for Gastric Carcinoma

Currently open trials in the same condition.

NCT07283939 — Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays · NA · recruiting
NCT07315750 — A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab Wi · Phase 3 · recruiting
NCT07139418 — The Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gas · recruiting
NCT07108855 — Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green Duri · Phase 1, PHASE2 · recruiting
NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting

Other China Medical University, China trials

Trials by the same sponsor.

NCT07519837 — Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics · NA · recruiting
NCT07388875 — Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC · Phase 2 · not yet recruiting
NCT07376499 — Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum a · Phase 2 · not yet recruiting
NCT07262840 — Health Behavior Change in High-Risk Colorectal Cancer Individuals · NA · recruiting
NCT07373964 — A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04443036 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by China Medical University, China
Last refreshed: 23 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04443036.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing